Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IPLEX vs FLEXERIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
FDA: Treatment of growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome, GH gene deletion, GH receptor defects) or with neutralizing antibodies to GH.,Off-label: Treatment of insulin-like growth factor-1 deficiency in adults; investigational in ALS and other neurodegenerative disorders.
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Terminal elimination half-life of 10-12 hours after subcutaneous administration, supporting twice-daily dosing.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Mecasermin (IGF-1) is metabolized by proteolytic degradation into amino acids; IGFBP-3 is also proteolytically degraded. No significant cytochrome P450 metabolism.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Renal excretion of intact IGF-I and its metabolites; approximately 70% eliminated via kidneys, with 30% biliary/fecal.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Approximately 90% bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3, and a minor fraction to albumin.
~93% bound to plasma proteins, primarily albumin.
Vd approximately 0.25-0.30 L/kg, indicating distribution primarily to extracellular fluid and well-perfused tissues.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Subcutaneous: Approximately 80-100%.
Oral: ~33% due to extensive first-pass metabolism.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30–50 m L/min), reduce dose by 25%; monitor IGF-I closely.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
Not studied in hepatic impairment; use with caution in Child-Pugh B or C; consider dose reduction based on clinical response and IGF-I monitoring.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
0.5-2 mg/kg subcutaneously once daily, titrated to achieve age-appropriate IGF-I levels.
Not recommended for use in children under 15 years old; safety and efficacy not established.
No specific dose adjustment; initiate at lower end of dosing range (0.5 mg/kg/day) due to potential for decreased renal function and increased sensitivity.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
Not available (no FDA boxed warning as of current labeling).
None
Hypoglycemia (especially in fasted state), intracranial hypertension, slipped capital femoral epiphysis, lymphatic tissue hypertrophy (e.g., tonsillar/adenoid enlargement), allergic reactions, and progression of pre-existing malignancies. Injection site reactions, lipohypertrophy. Risk of hyperglycemia if used in patients with diabetes. Monitor blood glucose, fundoscopy for papilledema, and for signs of hip/knee pain.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Hypersensitivity to mecasermin rinfabate or any component; active or suspected neoplasia; epiphyseal closure (skeletal maturity); children with closed epiphyses (except if indicated for severe IGF-1 deficiency with open epiphyses).
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
No specific food interactions reported. However, to minimize hypoglycemia risk, IPLEX should be administered immediately after a meal or snack. Avoid prolonged fasting. Alcohol use may increase hypoglycemia risk; avoid or limit alcohol consumption.
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of IGF-1 during organogenesis resulted in fetal growth retardation and increased skeletal abnormalities at doses similar to human exposure. Due to its growth-promoting effects, potential for teratogenicity, and interference with normal fetal development, IPLEX is contraindicated during pregnancy. First trimester: Risk of skeletal and growth abnormalities. Second and third trimesters: continued risk of abnormal fetal growth and development, including organ overgrowth or underdevelopment. Use only if maternal benefits outweigh potential fetal risks; however, generally avoided.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
It is unknown whether mecasermin rinfabate or its components (IGF-1, IGFBP-3) are excreted in human milk. Due to the potential for serious adverse reactions in the nursing infant, including growth stimulation and hypoglycemia, breast-feeding is not recommended during IPLEX therapy. No M/P ratio is available.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
No specific pharmacokinetic studies of IPLEX in pregnancy are available. The physiological changes of pregnancy (increased plasma volume, altered renal function, increased hepatic metabolism) may affect clearance of mecasermin rinfabate; however, due to its contraindication, dose adjustments during pregnancy are not recommended. If absolutely necessary, use the lowest effective dose and monitor for efficacy and adverse effects. No established dose adjustment guidelines exist.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (rh IGF-1) and its binding protein (rh IGFBP-3). It is indicated for growth failure in children with severe primary IGF-1 deficiency (e.g., Laron syndrome) or with GH gene deletion who have developed neutralizing antibodies to GH. Administer subcutaneously; dose is based on IGF-1 levels. Monitor for hypoglycemia, especially after injection; patients should eat shortly after dosing. Do not use in patients with closed epiphyses or active neoplasia. May cause lymphoproliferative disorders; monitor for splenomegaly, lymphadenopathy.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
Inject IPLEX within 20 minutes after a meal or snack to prevent hypoglycemia.,Rotate injection sites (abdomen, thigh, upper arm) to avoid lipohypertrophy.,Report symptoms of hypoglycemia (shakiness, sweating, confusion) or increased growth velocity.,Keep a log of blood glucose levels if advised by your doctor.,Store IPLEX in the refrigerator (2-8°C); do not freeze. Protect from light.,Do not share needles or pens; dispose of used needles in a sharps container.,Continue regular follow-up appointments for growth monitoring and blood tests.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IPLEX vs FLEXERIL, answered by our medical review team.
IPLEX is a Growth Factor that works by IPLEX (mecasermin rinfabate) is a complex of recombinant human insulin-like growth factor-1 (IGF-1) and its binding protein (IGFBP-3). It activates the IGF-1 receptor, promoting linear growth by stimulating chondrocyte proliferation in epiphyseal growth plates, as well as exerting anabolic effects on muscle and other tissues.. FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IPLEX and FLEXERIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IPLEX is: 0.5-2 mg/kg subcutaneously once daily, titrated based on IGF-I levels.. The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IPLEX and FLEXERIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IPLEX is classified as Category C. IPLEX (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF-binding protein-3. There are no adequate and well-controlled studies in . FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.